OGN Organon & Co.: רווח נקי למניה (EPS TTM)

Organon & Co. (OGN) combines patent protection for new drugs with an active pursuit of licenses through partnerships with biotech centers. The current level of rolling earnings per share demonstrates earnings dynamics, where the latest parameter is 0.77. High cash flow predictability is based on steady demand for established women's health brands, which guarantees reliable cash generation.

Investors assess fundamental capital risks by analyzing the real yield of each stock, stripping away market noise. Given the debt load of Organon & Co. (OGN) and its reliance on implant sales, the 12-month rolling EPS allows for the tracking of net profit per share over a year, confirming the business's ability to generate profit despite its obligations and determining the degree of the asset's undervaluation.